



The Nifty ended 1.20% up at 14,867.35. It opened on a positive note and remained extremely volatile throughout the session followed by sharp rise in the second half towards finishing off with a hammer candle. Candle pattern suggests strength in tomorrow's session, which may take the benchmark index higher towards 15,000 levels. Midway resistance is placed around 14,900 levels.

On the Nifty hourly chart; leading indicators turned upward following the sharp up move in the later half. Taking support around the critical MA band on intraday and losing in green suggests bullish momentum is likely to persist. However, taking out 14,900 decisively is the next challenge.

Nifty patterns on multiple time frames suggest; finishing off with a Hammer Candle is pointing towards range-bound oscillation with a positive bias in the price band of 14,700-15,000. Oversold Index majors on the hourly are likely to provide strength.

Nifty Crucial Supports & Resistances-

Supports- 14700, 14600 Resistances- 14900, 15000

Open Positional Calls-

T+15 Positional Buy-
|Cash Segment| BHEL @ 51-50, TGT- 64, SL - 43

T+2 Positional Buy-
|Cash Segment| TECH MAHINDRA @ 1007-1005, TGT- 1035, Closing SL- 990

Carry forward BTST-
|Cash Segment| COAL IND @ 132-131, TGT - 136, SL- 129

T+5 Positional Buy-
|Cash Segment| REC @ 131-130, TGT- 138, Closing SL- 126

T+3 Positional Buy-
|Cash Segment| Century Textiles @ 461-460, TGT- 480, Closing SL- 450

T+2 Positional Buy-
|Cash Segment| NALCO @ 56.50-56, TGT- 60, Closing SL- 54

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

Indian equities ended the weekly options expiry session and the holiday-shortened week on a positive note, closing near the highest point of the day.

The NIFTY index ended 1.20% higher at 14,867.35. The broader markets represented by the NIFTY 500 Index ended 1.34% higher, ending at 12,479. Among the sectorial indices, NIFTY Metal was the top gainer, gaining by 5.33%, followed by NIFTY PSU Bank, gaining by 2.63% higher. NIFTY FMCG was the top loser, losing by 0.16%.

JSW Steel was the top gainer, gaining by 8.60%, followed by Hindalco Industries and Tata Steel which gained by 7.16% & 6.31% respectively. HUL was the top loser, losing by 1.33%, followed by HDFC Life and Nestle India, which fell by 0.75% & 0.48% respectively.

The Advance: Decline ratio stood at 1593:353

Market Turnover (In Crore) 01-04-2021

Name	Last	Previous
NSE Cash	58765.51	56778.4
NSE F&O	*NA	3537748.85
BSE Cash	3,641.45	3,411.00
BSE F&O	*NA	218.48

FII Derivatives Flow (In Crore) 31-03-2021*

Instrument	Purchase	Sale	Net
Index Future	3377.43	5826.23	2448.8
Index Option	348208.51	345685.67	2522.84
Stock Future	12120.11	12755.88	635.77
Stock Option	7023.64	7054.84	31.2

Institutional Flow (In Crore) 01-04-2021

Institution	Purchase	Sale	Net
FII	7279.28	7129.87	149.41
DII	3621.88	3918.72	296.84

*Data not updated till 5.50pm

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
JSW Steel	8.60	16.33	35736230	11224460
Hindalco Industries	7.16	10.23	25631843	14929940
Tata Steel	6.31	22.80	36842098	31437970
Adani Ports & SE	4.82	4.16	15017049	13457180
Indusind Bank	4.07	3.61	7932671	5564009

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
TCS	0.40	1.41	4285076	3461718
HDFC Bank	0.46	0.54	17881881	10873710
Nestle India	0.48	3.86	83176	114014
HDFC Life	0.75	2.14	3443437	2415276
HUL	1.33	3.47	1532653	2444955

Bulk and Block Deals

<https://www.nseindia.com/products/content/Equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	50029.83	520.68	1.05	1.73	0.53	4.51	77.00
Nifty	14867.35	176.65	1.20	2.19	0.35	6.06	80.13
BSE M Cap	20516.40	335.09	1.66	2.12	1.21	12.95	98.42
BSE S Cap	21071.69	422.36	2.05	3.09	2.89	15.39	121.65
Nifty MC 100	24117.75	424.60	1.79	3.35	1.83	14.35	110.25
BSE Auto	22590.96	338.75	1.52	0.77	3.75	7.65	113.52
BSE Capgoods	21447.58	351.83	1.67	2.78	1.78	13.20	100.81
BSE FMCG	12867.07	8.33	0.06	2.57	6.40	1.35	29.99
BSE Metal	15127.33	776.72	5.41	12.26	8.02	30.33	170.73
BSE Oil&Gas	15085.73	265.27	1.79	1.01	4.79	6.69	53.81
BSE Healthcare	21528.53	200.32	0.94	3.26	1.87	1.49	79.86
BSE Power	2543.70	68.57	2.77	0.02	3.05	22.53	89.97
BSE Realty	2678.16	7.85	0.29	1.31	5.19	7.08	102.47
BSE ConsDur	32809.05	16.87	0.05	3.24	1.69	8.07	70.46
BSE Bank	38239.36	691.45	1.84	2.00	3.48	6.82	83.14
BSE IT	26769.77	226.53	0.85	2.14	8.26	9.39	120.76

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.72	0.02	1.19	5.30	21.36	88.32	194.87
UK	0.82	0.02	2.60	12.89	8.43	317.77	162.10
Brazil	4.28	0.06	1.36	2.93	9.26	33.04	3.35
Japan	0.11	0.02	18.95	31.40	27.10	438.10	769.23
Australia	1.84	0.05	3.02	9.65	10.24	83.18	171.53
India	6.17	0.02	0.31	0.70	1.08	5.13	0.46
Switzerland	0.30	0.02	7.64	11.38	8.82	46.18	9.76
Germany	0.30	0.01	4.11	20.83	8.98	46.57	33.62

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.11	0.27	0.37	0.76	0.60	0.07	3.32
USD Index	93.22	0.01	0.01	0.40	2.40	3.65	6.47
YUAN	6.57	0.02	0.33	0.43	1.65	0.72	8.00
GBP	1.38	0.00	0.01	0.36	1.01	0.82	11.42
EUR	1.17	0.00	0.08	0.21	2.57	3.90	7.07
YEN	110.79	0.07	0.06	1.44	3.64	6.85	3.27

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2046.00	57.00	2.71	6.75	23.92	49.78	227.88
Baltic Dirty	710.00	27.00	3.66	5.08	6.29	52.36	49.50
SG Dubai HY	0.12	0.33	73.33	180.00	109.16	111.01	123.08

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32981.55	85.41	0.26	1.73	4.59	7.76	57.48
Nasdaq	13246.87	201.48	1.54	2.20	2.52	2.78	79.97
S&P 500	3972.89	14.34	0.36	2.15	1.82	5.77	60.81
FTSE100	6746.77	28.33	0.42	1.01	2.33	4.36	23.60
CAC40	6077.80	9.68	0.16	2.09	4.90	9.47	44.44
DAX	15047.39	39.40	0.26	2.92	7.39	9.69	57.65
Mexico IPC	47246.26	658.74	1.38	1.16	5.50	7.21	40.23
Brazil Bovespa	116633.7	216.00	0.18	4.08	5.71	2.00	64.35
Russian RTS	1472.31	4.32	0.29	3.93	2.06	6.15	49.11
Japan Nikkei	29388.87	210.07	0.72	2.29	0.93	7.09	62.68
Hang Seng	28938.74	560.39	1.97	3.72	1.74	6.27	25.35
Taiwan Index	16571.28	140.15	0.85	3.18	3.92	12.48	71.48
Shanghai Comp	3466.33	24.42	0.71	3.05	1.20	0.19	24.66
KOSPI	3087.40	25.98	0.85	2.63	1.43	7.45	78.99
Malaysia KLCI	1582.64	9.13	0.58	0.94	0.81	2.74	18.92
Jakarta Comp	6011.46	25.93	0.43	1.82	5.47	0.54	32.65
Philippine SE	6443.09	102.46	1.57	0.83	6.25	9.76	19.13
Thai Exch	1595.12	7.91	0.50	1.53	6.10	10.06	40.14

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	59.89	0.78	1.32	2.36	1.15	23.54	195.13
BRENT Crude	63.38	0.67	1.07	2.61	0.62	22.74	65.43
Natural Gas	2.60	0.00	0.15	0.46	7.59	1.92	10.90

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1712.11	4.71	0.28	0.84	0.73	9.79	7.60
Silver(\$/Ounce)	24.32	0.09	0.38	2.94	8.45	7.87	74.22
Aluminium	2187.50	18.25	0.83	1.97	1.78	10.84	46.57
Copper	8787.75	17.50	0.20	2.07	3.85	13.40	77.93
Zinc	2805.25	8.00	0.29	0.69	1.07	2.78	48.05
Lead	1952.50	5.75	0.30	2.13	4.23	1.18	12.62

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	123.85	0.35	0.28	2.17	8.80	4.84	2.06
Cotton	80.98	0.10	0.12	3.24	11.56	2.90	53.37
Sugar	14.86	0.09	0.61	1.52	8.33	1.23	35.96
Wheat	614.75	3.25	0.53	0.37	5.46	3.87	9.09
Soybean	1438.25	1.50	0.10	1.70	3.38	10.06	70.61

Ashok Leyland's commercial vehicles sales at 17,231 units in March

Ashok Leyland reported total sales of 17,231 units of commercial vehicles in March. The company had sold a total of 2,126 units in March last year when sales were impacted by the nationwide lockdown due to COVID-19. Total medium and heavy commercial vehicle sales were at 11,101 units. It was at 1,778 units in the same month last year. Light commercial vehicle sales were at 6,130 units in March this year. It was at 348 units in the same month last year. Total domestic sales last month stood at 15,761 units. It was at 1,734 units in March last year.

Tata Motors reports sale of 66,609 units in domestic market in March

Tata Motors has sold a total of 66,609 units in the domestic market in March. The auto major had sold 11,012 units in the same month last year. Total commercial vehicle sales last month stood at 40,609 units. The company had dispatched just 7,123 units in the lockdown-impacted March 2020. Company continue to monitor and work on the supply chain to improve availability, especially of electronic components. Company are also reviewing our business continuity plans in view of the rising cases of COVID-19 in the country. Total passenger vehicle sales last month stood at 29,654 units. The company had sold 5,676 units in March 2020. For the 2020-21 fiscal, the company reported total sales of 4,64,515 units in the domestic market, up 5 per cent from 4,42,051 units in 2019-20. Total commercial vehicles stood at 2,62,773 units last fiscal, down 23 per cent from 3,40,700 units in 2019-20. Passenger vehicle sales during the 2020-21 fiscal stood at 2,22,025 units, up 69 per cent from 1,31,196 units in 2019-20.

Mahindra & Mahindra reports sale of 40,403 units in March

Mahindra & Mahindra (M&M) has sold a total of 40,403 units in March. The company had dispatched 6,679 units in March 2020 amid sales disruptions due to COVID-19 pandemic. The Mumbai-based automaker sold 16,700 passenger vehicles last month in the domestic market. It had dispatched 3,383 units in March 2020. It sold 21,577 commercial vehicles in the domestic market last month. The company had dispatched just 2,742 units in March 2020 due to coronavirus-led lockdown. The company's exports last month stood at 2,126 units. M&M overseas dispatches in March 2020 had stood at 554 units.

Maruti Suzuki reports sale of 1,67,014 units in March

Maruti Suzuki India reported total sales of 1,67,014 units in March. The company had sold 83,792 units in March last year amid nationwide lockdown due to the coronavirus pandemic. Its domestic sales stood at 1,49,518 units last month. The auto major had reported sales of 76,976 units in March 2020. Domestic sales in March 2020 had dropped about 48 per cent due to COVID related disruptions. It will be seen that domestic sales in March 2021 have only recovered to March 2019 levels. Sales of mini cars, comprising Alto and S-Presso, stood at 24,653 units last month. The company had sold 15,988 units in March 2020. Similarly, sales of compact segment vehicles, including models Swift, Celerio, Ignis, Baleno and Dzire, stood at 82,201 units last month. The company had reported dispatches of 40,519 cars in March last year. Sales of the mid-sized sedan Ciaz stood at 1,628 units last month. The model wholesales had stood at 1,863 units in March 2020. Utility vehicle sales, including Vitara Brezza, S-Cross and Ertiga, stood at 26,174 units last month. The company had sold 11,904 units in the year-ago month. Exports in March were at 11,597 units. It stood at 4,712 units in the corresponding month last year. For the fiscal year 2020-21, the auto major reported total sales of 14,57,861 units, down 6.7 per cent from 15,63,297 units in 2019-20. The company said its total domestic sales dropped to 13,23,396 units in 2020-21, from 14,36,124 in 2019-20.

Mahindra & Mahindra's tractor sales jump 128% y-o-y in March

Mahindra & Mahindra reported a 128 per cent y-o-y jump in total tractor sales to 30,970 units for March. Its total sales in March 2020 had stood at 13,613 units. Tractor sales in the domestic market grew 122 per cent to 29,817 units in the previous month, compared with 13,418 tractors sold a year ago. Sales in the overseas market surged 491 per cent to 1,153 units, from 195 tractors in the year-ago month. Company sold 29,817 tractors in the domestic market during March 2021 with a growth of 122 per cent over last year. The impact of lower base coupled with continued positive sentiments driven by healthy reservoir levels, higher MSP and increased liquidity have led to strong wholesale growth in March. The total tractor sales in the financial year 2020-21 rose 17.4 per cent to 3,54,498 units, from 3,01,915 tractors sold in 2019-20.

NCLT approves revival plan for Mumbai-based consumer firm Amar Remedies

The dedicated bankruptcy court has approved the resolution plan for the consumer and over the counter (OTC) products maker Amar Remedies submitted by little known PK Hospitality Services Pvt Ltd. The Mumbai-based Amar Remedies had approached the Mumbai bench of the National Company Law Appellate (NCLT) tribunal under Section 10 for self insolvency in June 2017. The company is known for selling toothpaste and pain relief balm under the brand name 'Amar'. The company owed about INR866 crore to its financial.

Tata Consumer Products to divest stake in US-based Empirical Group, Southern Tea

Tata Consumer Products Ltd (TCPL) on Thursday announced exit from its two US-based joint ventures by selling its stake to the JV partner Harris Tea Company LLC. TCPL step-down subsidiaries in the USA have decided to divest their entire membership interest in Empirical Group LLC and Southern Tea LLC to the JV partner Harris Tea Company LLC, USA (Harris Tea). The exits from both the JVs are in-line with TCPL's strategy to focus on the core branded business. The overseas step-down subsidiaries of TCPL in the USA have entered into an arrangement for the sale of its entire membership interest held in Empirical Group LLC (Empirical) and in Southern Tea, LLC (Southern Tea) to its Joint Venture Partner - Harris Tea Company LLC on March 31, 2021. However, the company did not share the amount, which it will receive from the divestment in both JVs. Empirical is engaged in the sale of tea and coffee for food services and contract customers and Southern Tea is a manufacturing entity managed by Harris Tea Company LLC.

NIIF invests INR2,100 crore in Manipal Hospitals

India's quasi sovereign wealth fund - National Investment and Infrastructure Fund Limited (NIIFL) has invested INR2,100 crore in Manipal Hospitals, one of India's largest multi-speciality healthcare provider. The investment, made through its NIIF Strategic Opportunities Fund (SOF), the direct private equity fund of NIIF, marks SOF's first investment in the Indian healthcare sector. Manipal Hospitals, headquartered in Bengaluru, has a major presence across India with 15 hospitals and a key focus on tertiary and quaternary care. It had recently acquired Columbia Asia Hospitals, a leading chain of hospitals.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Paramone Concepts Ltd	Corporate meeting effective 02-04-2021

Domestic Events

- India Foreign Exchange Reserve for March 26, 2021.

Global Events

- The U.S. Unemployment Rate for March 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com